Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis - 14/05/24
Doi : 10.1016/j.jaad.2024.01.080
Mika Yamanaka-Takaichi, MD, PhD a, Miki Watanabe, MD b, Nneka I. Comfere, MD a, c, Olayemi Sokumbi, MD d, e, Christeebella O. Akpala, RN f, Austin Todd, MS g, Emily L. Branch, CCRP h, Aaron R. Mangold, MD i, Sho Hiroyasu, MD, PhD b, Daisuke Tsuruta, MD, PhD b, Afsaneh Alavi, MD a, ⁎ 
a Department of Dermatology, Mayo Clinic, Rochester, Minnesota
b Department of Dermatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
c Department of Laboratory & Pathology, Mayo Clinic, Rochester, Minnesota
d Department of Dermatology, Mayo Clinic, Jacksonville, Florida
e Department of Laboratory & Pathology, Mayo Clinic, Jacksonville, Florida
f Mayo Clinic Alix School of Medicine – Minnesota Campus, Mayo Clinic College of Medicine and Science, Rochester, Minnesota
g Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota
h Division of Research Administrative Services, Mayo Clinic, Scottsdale, Arizona
i Department of Dermatology, Mayo Clinic, Scottsdale, Arizona
∗Correspondence to: Afsaneh Alavi, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, 55905 MNDepartment of DermatologyMayo Clinic200 First St SWRochesterMN55905
Key words : acute generalized exanthematous pustulosis, differential diagnosis, generalized pustular psoriasis, histopathology, pustular psoriasis
| Funding sources: This study was supported in part by the Japanese Dermatological Association Grant-In-Aid for Study Abroad that provided funding for Dr Yamanaka-Takaichi. The Department of Dermatology, Mayo Clinic, provided financial support for statistical analysis. The Scientific Publications staff at Mayo Clinic provided proofreading, administrative, and clerical support. |
|
| Presented at the 11th International Congress of Severe Cutaneous Adverse Reactions (iSCAR 2023); Yuzawa, Niigata, Japan; May 14-15, 2023. |
|
| Patient consent: Informed consent was waived. |
|
| IRB approval status: Mayo Clinic Institutional review board (#22-01241) and Osaka Metropolitan University Institutional Review Board (#2022-199). |
© 2024
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 90 - N° 6
P. 1289-1291 - juin 2024 Retour au numéro
Article précédent
- Prevalence and risk factors for development of recurrent calciphylaxis
- Joyce Xia, Alice J. Tan, Colleen K. Gabel, Emily D. Nguyen, Sidharth Chand, Renajd Rrapi, Allison S. Dobry, Anna Cristina Garza-Mayers, Lauren N. Ko, Radhika Shah, Jessica St. John, Sagar U. Nigwekar, Daniela Kroshinsky
- Sepsis-like features in hidradenitis suppurativa flares requiring admission: A retrospective cohort study
- Duaa AbdelHameid, Laura Wang, Melissa M. Mauskar, Arturo R. Dominguez, Cristina Thomas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?